Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335362 | 0.97 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL21436918 | 0.97 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL1333027 | 0.97 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL1001552 | 0.97 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL2507860 | 0.97 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL18324135 | 0.97 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL17879364 | 0.97 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL18107259 | 0.94 | DNM1 (0.52) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL18107402 | 0.94 | DNM1 (0.52) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL18107386 | 0.94 | DNM1 (0.52) | TSHRTHRBLMNADNM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050104042-A1 | Process for the synthesis of amine ethers from secondary amino oxides | CIBA SPECIALTY CHEMICALS CORP. | 2005-05-19 | — | — | US | disclosed |
| EP-1463717-A2 | PROCESS FOR THE SYNTHESIS OF AMINE ETHERS FROM SECONDARY AMINO OXIDES AND USES | Ciba SC Holding AG (CH) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003045919-A2 | PROCESS FOR THE SYNTHESIS OF AMINE ETHERS FROM SECONDARY AMINO OXIDES AND USES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050104042-A1 | Process for the synthesis of amine ethers from secondary amino oxides | AOC2, PPOX, DAO | TSHR 1027/4885THRB 1184/4885LMNA 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.